DK1479691T3 - Langvarigt aktive fuionspeptidinhibitorer for HIV infektion - Google Patents

Langvarigt aktive fuionspeptidinhibitorer for HIV infektion

Info

Publication number
DK1479691T3
DK1479691T3 DK04015696T DK04015696T DK1479691T3 DK 1479691 T3 DK1479691 T3 DK 1479691T3 DK 04015696 T DK04015696 T DK 04015696T DK 04015696 T DK04015696 T DK 04015696T DK 1479691 T3 DK1479691 T3 DK 1479691T3
Authority
DK
Denmark
Prior art keywords
virus
fuion
acting
long
hiv infection
Prior art date
Application number
DK04015696T
Other languages
Danish (da)
English (en)
Inventor
Dominique P Bridon
Martin Robitaille
Dong Xie
Jun Liang
John Erickson
Grant A Krafft
Elena Afonina
Meyer Sandra De
Original Assignee
John Erickson
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Erickson, Conjuchem Biotechnologies Inc filed Critical John Erickson
Application granted granted Critical
Publication of DK1479691T3 publication Critical patent/DK1479691T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04015696T 2001-05-31 2002-05-31 Langvarigt aktive fuionspeptidinhibitorer for HIV infektion DK1479691T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29424101P 2001-05-31 2001-05-31
PCT/CA2002/000806 WO2002096935A2 (en) 2001-05-31 2002-05-31 Long lasting fusion peptide inhibitors for hiv infection

Publications (1)

Publication Number Publication Date
DK1479691T3 true DK1479691T3 (da) 2007-03-12

Family

ID=23132509

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04015696T DK1479691T3 (da) 2001-05-31 2002-05-31 Langvarigt aktive fuionspeptidinhibitorer for HIV infektion

Country Status (12)

Country Link
US (2) US7741453B2 (es)
EP (1) EP1390399B1 (es)
JP (2) JP4463545B2 (es)
AT (3) ATE295370T1 (es)
AU (1) AU2002302277A1 (es)
CA (1) CA2448891A1 (es)
DE (3) DE60229677D1 (es)
DK (1) DK1479691T3 (es)
ES (2) ES2277173T3 (es)
HK (1) HK1071379A1 (es)
PT (1) PT1479691E (es)
WO (1) WO2002096935A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2209885T3 (es) * 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
US7582301B1 (en) * 1999-05-17 2009-09-01 Conjuchem Biotechnologies, Inc. Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
CA2436399A1 (en) * 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
EP1620120A4 (en) * 2003-03-24 2010-01-06 Sequoia Pharmaceuticals Inc BIOLOGICAL ACTIVE CONJUGATES WITH LONG-TERM EFFECT
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
JP4838722B2 (ja) 2003-10-24 2011-12-14 ゲンシア コーポレーション ポリヌクレオチドを送達する方法、及び送達用組成物
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
DE602005014969D1 (de) * 2004-04-23 2009-07-30 Conjuchem Biotechnologies Inc Verfahren zur aufreinigung von albumin-konjugaten
WO2005108418A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
MX2008008076A (es) * 2005-12-22 2008-11-28 Conjuchem Biotechnologies Inc Procesos para la produccion de conjugados preformados de albumina y un agente terapeutico.
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
US20090088377A1 (en) * 2007-05-16 2009-04-02 Conjuchem Biotechnologies, Inc. Cysteic acid derivatives of anti-viral peptides
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
WO2009075859A2 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
US8815295B1 (en) 2011-12-22 2014-08-26 Alabama State University Anti respiratory syncytial virus peptide functionalized gold nanoparticles
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994002505A1 (en) * 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
AU3370795A (en) 1994-08-15 1996-03-07 B-Level Corp. Auxiliary surface-forming member for construction elements
JP3871713B2 (ja) * 1995-05-10 2007-01-24 協和醗酵工業株式会社 新規毒素複合体
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
EP1007561B1 (en) 1997-11-07 2002-04-17 Conjuchem, Inc. Novel conjugates of opioids and endogenous carriers
DE69806066T2 (de) 1997-11-07 2003-02-06 Conjuchem, Inc. Affinitätsmarkierer für menschliches serum albumin
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
WO1999048536A2 (en) 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
BR9914519A (pt) * 1998-10-13 2001-07-03 Univ Georgia Res Found Peptìdios bioativos estabilizados e métodos de identificação, sìntese e uso
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1149115A4 (en) 1999-01-08 2005-11-02 Panacos Pharmaceuticals Inc TECHNIQUES FOR ELICITATION OF NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
WO2000070665A2 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US7582301B1 (en) * 1999-05-17 2009-09-01 Conjuchem Biotechnologies, Inc. Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
AU765753B2 (en) 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
CA2383798A1 (en) 1999-09-07 2001-03-15 Conjuchem Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) * 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
ES2296665T3 (es) 1999-12-16 2008-05-01 Whitehead Institute For Biomedical Research Proteina cinco-helice.
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
EP1542718B1 (en) 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection
CN101152574A (zh) 2002-09-27 2008-04-02 唐纳士公司 用于预防和治疗获得性免疫缺陷综合症的协同组合物
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
WO2005007831A2 (en) 2003-07-18 2005-01-27 Vanderbilt University Compositions of protein mimetics and methods of using same against hiv-1, sars-cov and the like
DE602005014969D1 (de) 2004-04-23 2009-07-30 Conjuchem Biotechnologies Inc Verfahren zur aufreinigung von albumin-konjugaten
WO2005108418A1 (en) 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
MX2008008076A (es) 2005-12-22 2008-11-28 Conjuchem Biotechnologies Inc Procesos para la produccion de conjugados preformados de albumina y un agente terapeutico.

Also Published As

Publication number Publication date
US20050065075A1 (en) 2005-03-24
WO2002096935A3 (en) 2003-10-02
ATE295370T1 (de) 2005-05-15
JP4463545B2 (ja) 2010-05-19
ES2277173T3 (es) 2007-07-01
WO2002096935A2 (en) 2002-12-05
JP2005500274A (ja) 2005-01-06
JP2008308506A (ja) 2008-12-25
EP1390399B1 (en) 2005-05-11
CA2448891A1 (en) 2002-12-05
DE60216151T2 (de) 2007-09-27
AU2002302277A1 (en) 2002-12-09
PT1479691E (pt) 2007-02-28
ES2242860T3 (es) 2005-11-16
DE60204137T2 (de) 2006-01-26
EP1390399A2 (en) 2004-02-25
DE60229677D1 (de) 2008-12-11
DE60216151D1 (de) 2006-12-28
US20110166061A1 (en) 2011-07-07
ATE412667T1 (de) 2008-11-15
ATE345353T1 (de) 2006-12-15
US7741453B2 (en) 2010-06-22
HK1071379A1 (en) 2005-07-15
DE60204137D1 (de) 2005-06-16

Similar Documents

Publication Publication Date Title
DK1479691T3 (da) Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
ATE387208T1 (de) Antivirale mittel aus pflanzenextrakten und deren verwendung zur behandlung viraler infektionen
WO2008144584A3 (en) Cysteic acid derivatives of anti-viral peptides
EA200700243A1 (ru) Способы лечения гепатита с
DE602006015861D1 (de) Antivirale verbindungen
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
TW200733953A (en) Materials and methods for treating viral infections
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
WO2005007078A3 (en) Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
DE60136381D1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
DK1765370T3 (da) Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS
ATE281179T1 (de) Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
WO2007002172A3 (en) Hiv-1 protease inhibitors
MX9700414A (es) Agentes antivirales de difluoroestatona.
EP1752469A3 (en) Long lasting fusion peptide inhibitors for HIV infection
ATE478679T1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
CY1105997T1 (el) Mακρας διαρκειας αναστολεις πεπτιδιου συντηξης για μολυνση hiv
WO2008144590A3 (en) Long lasting modified antifusogenic peptide for preventing hiv infection
EP1546415A4 (en) ANTI-TSG101 ANTIBODIES AND USES THEREOF FOR TREATING VIRAL INFECTIONS
ATE481413T1 (de) Glutathionderivate und deren verwendung zur behandlung von viralen erkrankungen
ATE375800T1 (de) Anti-hiv und anti-tumor lysozympeptide sowie fragmente
WO2004108128A1 (fr) Utilisation de bullatacine dans la fabrication de medicaments anti-sida